Sermorelin

peptideresearch peptide

Research chemical — not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.

At a glance

Best for
Not established — investigational
Main caution
No longer an FDA-approved product; unregulated/compounded supply and no long-term safety data for off-label use
Evidence strength: Some historical clinical/diagnostic use; no current approval and limited long-term human data

What is it

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone (GHRH), which stimulates the pituitary to produce and release growth hormone. It was historically FDA-approved (as Geref) for diagnostic testing and pediatric growth-hormone-deficiency evaluation, but that product was withdrawn from the U.S. market and it is no longer an approved drug; it is sometimes prepared by compounding pharmacies off-label. As a marketed 'research' or compounded peptide it lacks current FDA approval and standardized regulation, and robust long-term safety/efficacy data for anti-aging or performance use do not exist. It is not a dietary supplement and is often sold 'for research use only.'

Is it worth it for you?

Probably skip if…

  • You expect a currently approved product — the original FDA-approved drug was withdrawn
  • You would buy from 'research use only' vendors with no purity, sterility, or dosing oversight
  • You are not prepared for limited long-term safety data for anti-aging or performance use
  • You are uncomfortable with self-injection risks such as infection and contamination
  • You compete in sport — GHRH analogs are prohibited under WADA rules

Safety

Common side effects

Reported historically: injection-site redness/pain/swelling, flushing, headache, occasional nausea or dizziness

Serious risks

  • Unregulated purity, sterility, and dosing when obtained from research vendors
  • Unknown long-term effects of sustained GH/IGF-1 elevation outside its original diagnostic indication
  • Injection-related infection and contamination risk
  • Rare hypersensitivity reactions; no clinical monitoring when self-administered

Who should avoid it

  • Anyone without direct medical supervision
  • Pregnancy and breastfeeding
  • People with cancer or a history of cancer
  • People with diabetes or impaired glucose tolerance (without supervision)
  • Competitive athletes subject to anti-doping rules

Pregnancy & breastfeeding

Avoid — no safety data for this use.

Choosing a product

Be skeptical of

  • 'Proven' anti-aging or performance benefits in healthy adults
  • Vendors selling 'for research use only' product for human injection
  • Implying current FDA approval or equivalence to prescription growth hormone

Track Sermorelin with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.